Yahoo Finance

New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...
Healthline

Dosage Details for Vabysmo

Vabysmo (faricimab-svoa) is a prescription drug designed to treat certain types of eye conditions. Your dosage and dosing schedule depend on the condition the drug is prescribed to treat. Vabysmo is ...
Yahoo Finance

New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration

In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one Patients treated with Vabysmo ...
Nasdaq

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

– If approved by the FDA, RVO would be Vabysmo’s third indication in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – – Vabysmo is the first and only treatment ...
Pharm Exec

Fighting Vision Loss: Vabysmo

Use against pair of pathways could pave way for standout in stocked eye disease market. With Roche/Genentech’s sights set on helping patients suffering from blinding eye conditions, it turned to an ...
Business Wire

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
Nasdaq

New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart – – Detailed results from two global Phase III RVO studies will be presented at ...
Healthline

Vabysmo: How It Works

Vabysmo (faricimab-svoa) is a prescription drug that works to treat a type of macular degeneration and other eye conditions by blocking certain proteins in your body. Your response to this drug may ...
Medical News Today

Vabysmo injection side effects and how to manage them

As with other drugs, Vabysmo (faricimab-svoa) can cause side effects, such as eye irritation and vision changes. If you are not able to tolerate side effects of Vabysmo, talk with your doctor or ...
Business Wire

New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss

‒ In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one – ‒ ...
PharmiWeb

Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies Regulatory applications for Vabysmo in RVO are under review by health ...